Table 1-.
Treatment Assigned |
|||
---|---|---|---|
Hypothermia (N = 321) |
Normothermia (N = 303) |
P-value | |
Age at Randomization (years) | 0.0721 | ||
N | 321 | 303 | |
Median [Q1 - Q3] | 1.7 [0.4 - 7.6] | 1.2 [0.3 - 6.5] | |
Age Group at Randomization | 0.5092 | ||
< 2 years | 173 (53.9%) | 177 (58.4%) | |
2-11 years | 96 (29.9%) | 80 (26.4%) | |
>= 12 years | 52 (16.2%) | 46 (15.2%) | |
Male | 199 (62.0%) | 193 (63.7%) | 0.6602 |
Pre-existing Conditions | |||
No pre-existing condition | 94 (29.3%) | 88 (29.0%) | 0.9472 |
Lung or airway disease | 87 (27.1%) | 89 (29.4%) | 0.5292 |
Neurologic condition | 87 (27.1%) | 67 (22.1%) | 0.1482 |
Gastrointestinal disorder | 69 (21.5%) | 72 (23.8%) | 0.4992 |
Prenatal condition | 59 (18.4%) | 64 (21.1%) | 0.3892 |
Congenital heart disease | 111 (34.6%) | 112 (37.0%) | 0.5352 |
Other pre-existing condition | 46 (14.3%) | 53 (17.5%) | 0.2802 |
Primary aetiology of cardiac arrest | 0.6632 | ||
Cardiac | 99 (30.8%) | 91 (30.0%) | |
Respiratory | 156 (48.6%) | 157 (51.8%) | |
Other/Unknown | 66 (20.6%) | 55 (18.2%) | |
Initial rhythm noted by EMS or hospital | 0.9032 | ||
Asystole | 99 (30.8%) | 97 (32.0%) | |
Bradycardia | 104 (32.4%) | 104 (34.3%) | |
Pulseless electrical activity (PEA) | 58 (18.1%) | 54 (17.8%) | |
Ventricular fibrillation or tachycardia | 31 (9.7%) | 26 (8.6%) | |
Unknown | 29 (9.0%) | 22 (7.3%) | |
Estimated duration of chest compressions | 0.1331 | ||
N | 312 | 300 | |
Median [Q1 - Q3] | 24.5 [10.5 - 40.0] | 25.5 [12.5 - 48.0] | |
Time of ROSC | 0.9612 | ||
Day | 222 (69.2%) | 209 (69.0%) | |
Night | 99 (30.8%) | 94 (31.0%) | |
Day of ROSC | 0.6982 | ||
Weekday | 248 (77.3%) | 238 (78.5%) | |
Weekend | 73 (22.7%) | 65 (21.5%) | |
Total known adrenaline (epinephrine) doses3 | 0.3371 | ||
N | 320 | 302 | |
Median [Q1 - Q3] | 3.0 [2.0 - 6.0] | 4.0 [2.0 - 7.0] | |
ECMO4 | 87 (27.1%) | 97 (32.0%) | 0.1792 |
P-value is based on the Wilcoxon rank-sum test.
Chi-squared test of no association.
Administered by EMS and at hospital.
Started at or before treatment and not stopped before treatment initiation.